The role of CD200 in immunity to B cell lymphoma

Journal of Leukocyte Biology

Volumn 88, Issue 2, 2010, Pages 361-372

  Wong, Karrie K ^a   Khatri, Ismat ^a   Shaha, Suchinta ^b   Spaner, David E ^b,c   Gorczynski, Reginald M ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b Sunnybrook Health Sciences Centre   (Canada)

^c DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

Cancer; Cancer immunology; Immune evasion

Indexed keywords

CD200 ANTIGEN; GAMMA INTERFERON; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD200; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIGENS, CD200; CYTOKINE; LEUKOCYTE ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL KILLING; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; LYMPHOMA CELL; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TUMOR IMMUNITY; WESTERN BLOTTING; B CELL LYMPHOMA; BIOSYNTHESIS; CYTOTOXICITY; DRUG EFFECT; IMMUNITY; IMMUNOLOGY; TUMOR CELL CULTURE; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; CELL LINE, TUMOR; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNITY; LYMPHOMA, B-CELL; RNA, SMALL INTERFERING; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 77956408970     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.1009686     Document Type: Article

References (43)

1. Shaffer, A. L., Rosenwald, A., Staudt, L. M. (2002) Lymphoid malignancies: the dark side of B-cell differentiation. Nat. Rev. Immunol. 2, 920-932. (Pubitemid 37323213)
2. Spaner, D. E., Masellis, A. (2007) Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia. Leukemia 21, 53-60. (Pubitemid 44921834)
3. Tomic, J., White, D., Shi, Y., Mena, J., Hammond, C., He, L., Miller, R. L., Spaner, D. E. (2006) Sensitization of IL-2 signaling through TLR-7 enhances B lymphoma cell immunogenicity. J. Immunol. 176, 3830-3839. (Pubitemid 43364032)
4. McWhirter, J. R., Kretz-Rommel, A., Saven, A., Maruyama, T., Potter, K. N., Mockridge, C. I., Ravey, E. P., Qin, F., Bowdish, K. S. (2006) Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc. Natl. Acad. Sci. USA 103, 1041-1046. (Pubitemid 43212218)
5. Moreaux, J., Veyrune, J. L., Reme, T., De Vos, J., Klein, B. (2008) CD200: a putative therapeutic target in cancer. Biochem. Biophys. Res. Commun. 366, 117-122. (Pubitemid 350297222)
6. Petermann, K. B., Rozenberg, G. I., Zedek, D., Groben, P., McKinnon, K., Buehler, C., Kim, W. Y., Shields, J. M., Penland, S., Bear, J. E., Thomas, N. E., Serody, J. S., Sharpless, N. E. (2007) CD200 is induced by ERK and is a potential therapeutic target in melanoma. J. Clin. Invest. 117, 3922-3929.
7. Siva, A., Xin, H., Qin, F., Oltean, D., Bowdish, K. S., Kretz-Rommel, A. (2008) Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200. Cancer Immunol. Immunother. 57, 987-996.
8. Tonks, A., Hills, R., White, P., Rosie, B., Mills, K. I., Burnett, A. K., Darley, R. L. (2007) CD200 as a prognostic factor in acute myeloid leukemia. Leukemia 21, 566-568.
9. Kawasaki, B. T., Mistree, T., Hurt, E. M., Kalathur, M., Farrar, W. L. (2007) Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells. Biochem. Biophys. Res. Commun. 364, 778-782. (Pubitemid 350103695)
10. Gorczynski, R. M. (2005) CD200 and its receptors as targets for immunoregulation. Curr. Opin. Investig. Drugs 6, 483-488.
11. Gorczynski, R. M., Chen, Z., Hu, J., Kai, Y., Lei, J. (2001) Evidence of a role for CD200 in regulation of immune rejection of leukemic tumor cells in C57BL/6 mice. Clin. Exp. Immunol. 126, 220-229. (Pubitemid 32995135)
12. Kretz-Rommel, A., Qin, F., Dakappagari, N., Ravey, E. P., McWhirter, J., Oltean, D., Frederickson, S., Maruyama, T., Wild, M. A., Nolan, M. J., Wu, D., Springhorn, J., Bowdish, K. S. (2007) CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy. J. Immunol. 178, 5595-5605.
13. Pallasch, C. P., Ulbrich, S., Brinker, R., Hallek, M., Uger, R. A., Wendtner, C. M. (2009) Disruption of T cell suppression in chronic lymphocytic leukemia by CD200 blockade. Leuk. Res. 33, 460-464.
14. Shi, Y., White, D., He, L., Miller, R. L., Spaner, D. E. (2007) Toll-like receptor-7 tolerizes malignant B cells and enhances killing by cytotoxic agents. Cancer Res. 67, 1823-1831.
15. Tweeddale, M. E., Lim, B., Jamal, N., Robinson, J., Zalcberg, J., Lockwood, G., Minden, M. D., Messner, H. A. (1987) The presence of clonogenic cells in high-grade malignant lymphoma: a prognostic factor. Blood 69, 1307-1314. (Pubitemid 17085284)
16. Hammond, C., Shi, Y., Mena, J., Tomic, J., Cervi, D., He, L., Millar, A. E., Debenedette, M., Schuh, A. C., Baryza, J. L., Wender, P. A., Radvanyi, L., Spaner, D. E. (2005) Effect of serum and antioxidants on the immunogenicity of protein kinase C-activated chronic lymphocytic leukemia cells. J. Immunother. 28, 28-39.
17. Chen, D. X., Gorczynski, R. M. (2005) Discrete monoclonal antibodies define functionally important epitopes in the CD200 molecule responsible for immunosuppression function. Transplantation 79, 282-288.
18. Gorgun, G., Holderried, T. A., Zahrieh, D., Neuberg, D., Gribben, J. G. (2005) Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J. Clin. Invest. 115, 1797-1805. (Pubitemid 40979718)
19. Flies, D. B., Chen, L. (2007) The new B7s: playing a pivotal role in tumor immunity. J. Immunother. 30, 251-260.
20. Crispen, P. L., Sheinin, Y., Roth, T. J., Lohse, C. M., Kuntz, S. M., Frigola, X., Thompson, R. H., Boorjian, S. A., Dong, H., Leibovich, B. C., Blute, M. L., Kwon, E. D. (2008) Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin. Cancer Res. 14, 5150-5157.
21. Roth, T. J., Sheinin, Y., Lohse, C. M., Kuntz, S. M., Frigola, X., Inman, B. A., Krambeck, A. E., McKenney, M. E., Karnes, R. J., Blute, M. L., Cheville, J. C., Sebo, T. J., Kwon, E. D. (2007) B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res. 67, 7893-7900.
22. Oikonomopoulou, K., Li, L., Zheng, Y., Simon, I., Wolfert, R. L., Valik, D., Nekulova, M., Simickova, M., Frgala, T., Diamandis, E. P. (2008) Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel. Br. J. Cancer 99, 1103-1113.
23. Comin-Anduix, B., Lee, Y., Jalil, J., Algazi, A., de la Rocha, P., Camacho, L. H., Bozon, V. A., Bulanhagui, C. A., Seja, E., Villanueva, A., Straatsma, B. R., Gualberto, A., Economou, J. S., Glaspy, J. A., Gomez-Navarro, J., Ribas, A. (2008) Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J. Transl. Med. 6, 22.
24. Rezvany, M. R., Jeddi-Tehrani, M., Rabbani, H., Lewin, N., Avila-Carino, J., Osterborg, A., Wigzell, H., Mellstedt, H. (2000) Autologous T lymphocytes may specifically recognize leukemic B cells in patients with chronic lymphocytic leukemia. Br. J. Haematol. 111, 608-617.
25. Rezvany, M. R., Jeddi-Tehrani, M., Wigzell, H., Osterborg, A., Mellstedt, H. (2003) Leukemia-associated monoclonal and oligoclonal TCR-BV use in patients with B-cell chronic lymphocytic leukemia. Blood 101, 1063-1070. (Pubitemid 36139380)
26. Kofler, D. M., Mayr, C., Wendtner, C. M. (2006) Current status of immunotherapy in B cell malignancies. Curr. Drug Targets 7, 1371-1374.
27. Mayr, C., Kofler, D. M., Buning, H., Bund, D., Hallek, M., Wendtner, C. M. (2005) Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells. Blood 106, 3223-3226.
28. Hus, I., Schmitt, M., Tabarkiewicz, J., Radej, S., Wojas, K., Bojarska-Junak, A., Schmitt, A., Giannopoulos, K., Dmoszynska, A., Rolinski, J. (2008) Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response. Leukemia 22, 1007-1017. (Pubitemid 351689883)
29. Palma, M., Adamson, L., Hansson, L., Kokhaei, P., Rezvany, R., Mellstedt, H., Osterborg, A., Choudhury, A. (2008) Development of a dendritic cell-based vaccine for chronic lymphocytic leukemia. Cancer Immunol. Immunother. 57, 1705-1710.
30. Kretz-Rommel, A., Qin, F., Dakappagari, N., Cofiell, R., Faas, S. J., Bowdish, K. S. (2008) Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapy. J. Immunol. 180, 699-705.
31. Dunn, G. P., Koebel, C. M., Schreiber, R. D. (2006) Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6, 836-848.
32. Clark, D. A., Wong, K., Banwatt, D., Chen, Z., Liu, J., Lee, L., Gorczynski, R. M., Blajchman, M. A. (2008) CD200-dependent and nonCD200-dependent pathways of NK cell suppression by human IVIG. J. Assist. Reprod. Genet. 25, 67-72.
33. Ramsay, A. G., Johnson, A. J., Lee, A. M., Gorgun, G., Le Dieu, R., Blum, W., Byrd, J. C., Gribben, J. G. (2008) Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J. Clin. Invest. 118, 2427-2437. (Pubitemid 351949771)
34. Ramsay, A. G., Gribben, J. G. (2009) Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug. Haematologica 94, 1198-1202.
35. Hegde, U., Chhabra, A., Chattopadhyay, S., Das, R., Ray, S., Chakraborty, N. G. (2008) Presence of low dose of fludarabine in cultures blocks regulatory T cell expansion and maintains tumor-specific cytotoxic T lymphocyte activity generated with peripheral blood lymphocytes. Pathobiology 75, 200-208.
36. Mone, A. P., Cheney, C., Banks, A. L., Tridandapani, S., Mehter, N., Guster, S., Lin, T., Eisenbeis, C. F., Young, D. C., Byrd, J. C. (2006) Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. Leukemia 20, 272-279. (Pubitemid 43148665)
37. Gorczynski, R. M., Chen, Z., Lee, L., Yu, K., Hu, J. (2002) Anti-CD200R ameliorates collagen-induced arthritis in mice. Clin. Immunol. 104, 256-264. (Pubitemid 35191102)
38. Gorczynski, R. M., Chen, Z., Yu, K., Hu, J. (2001) CD200 immunoadhesin suppresses collagen-induced arthritis in mice. Clin. Immunol. 101, 328-334.
39. Chitnis, T., Imitola, J., Wang, Y., Elyaman, W., Chawla, P., Sharuk, M., Raddassi, K., Bronson, R. T., Khoury, S. J. (2007) Elevated neuronal expression of CD200 protects Wlds mice from inflammation-mediated neurodegeneration. Am. J. Pathol. 170, 1695-1712. (Pubitemid 47339314)
40. Bell, J. H., Herrera, A. H., Li, Y., Walcheck, B. (2007) Role of ADAM17 in the ectodomain shedding of TNF-α and its receptors by neutrophils and macrophages. J. Leukoc. Biol. 82, 173-176. (Pubitemid 47026423)
41. Matthews, V., Schuster, B., Schutze, S., Bussmeyer, I., Ludwig, A., Hundhausen, C., Sadowski, T., Saftig, P., Hartmann, D., Kallen, K. J., Rose-John, S. (2003) Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J. Biol. Chem. 278, 38829-38839. (Pubitemid 37221782)
42. Sanderson, M. P., Erickson, S. N., Gough, P. J., Garton, K. J., Wille, P. T., Raines, E. W., Dunbar, A. J., Dempsey, P. J. (2005) ADAM10 mediates ectodomain shedding of the β cellulin precursor activated by p-aminophenylmercuric acetate and extracellular calcium influx. J. Biol. Chem. 280, 1826-1837.
43. Wong, K., Shaha, S., Spaner, D.S., Gorczynski, R. (2009) Potential role for serum soluble CD200 in human chronic lymphocytic leukemia. J. Immunol. 182, 88.15 (abs.).